CD276 and prostate carcinoma: This method not only reflects the temporal dynamics of B7-H3 expression but also offers more treatment options for patients, indicating that B7-H3 is a biomarker and potential therapeutic target for prostate cancer (114).Furthermore, numerous studies have indicated that B7-H3 is a novel and promising therapeutic target for prostate cancer (109, 115, 116).